article thumbnail

STAT+: Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show

STAT

The FDA’s months-long internal examination of the LBP yielded a series of documents seen by STAT, including a lengthy review, completed in August 2019, of the Mount Sinai study. The review, which lists consultations with 16 different FDA officials, was scathing.

article thumbnail

NIH spending for drugs approved 2010-2019 lower than industry spending, study finds

European Pharmaceutical Review

New research published in JAMA Health Forum has documented that the US National Institutes of Health (NIH) spent $8.1 billion for phased clinical trials of US Food and Drug Administration (FDA)-approved drugs between 2010-2019. This was ~10 percent of reported industry spending. billion (3.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Juul’s internal playbook opens a rare window into influence in Washington

STAT

WASHINGTON — A new trove of internal emails and other documents from the e-cigarette maker Juul reveals the company’s extensive behind-the-scenes efforts to promote its interests in Washington — a rare insight into the otherwise opaque methods corporations use to influence the government.

article thumbnail

ICYMI: Cancer death rate continues to decline due to treatment advances

PhRMA

decrease between 2019 and 2020 alone, increasingly reflects advances in prevention and treatment—including new medicines which have improved survival across a range of cancers. This report is the latest to document this progress. The report notes the continued decline in death rates since 1991, including a 1.5%

article thumbnail

STAT+: As regulators play catch up with AI, tech startups say uncertainty is slowing them down

STAT

health care market , AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. As they race for a slice of the $4 trillion U.S. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

article thumbnail

EMA publishes updated Q&A for ICH M10

European Pharmaceutical Review

The European Medicines Agency (EMA) has published an updated Q&A document regarding ICH M10 ‘Bioanalytical Method Validation and Study Sample Analysis’. Implementation of the ICH M10 document The EU date of coming into effect of the core ICH M10 document and the corresponding Q&As was 21 January 2023.

article thumbnail

STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more

STAT

Merdad Parsey, who joined Gilead in 2019, will stay in his post until the first quarter of next year as the company looks for a successor. Gilead  Gilead has faced multiple setbacks in its attempt to move away from its stronghold in virology and into other areas like cancer. The EC says she did not keep the messages.